Malaria Vaccine Shows Some Protection For One Year In Clinical Trial

New York Times: A Malaria Vaccine Has Some Success in Testing
“An experimental malaria vaccine tested in varying doses provided 55 percent protection for one year to a few volunteers, a study released Monday said…” (McNeil, 5/9).

Science Speaks: Malaria vaccine candidate shows longer protection, promise, direction of next steps
“…The results, while still limited, represent the continued advance of an approach that scientists at the National Institute of Allergy and Infectious Disease first noted promise nearly five years ago…” (Barton, 5/9).

TIME: Malaria Vaccine Shows Strongest Protection Yet
“…Doctors and scientists want a vaccine that offers protection for longer than [one year], but the new study, published Monday in the journal Nature Medicine, has shown the longest duration of protection so far. The vaccine, called PfSPZ is developed by the biotech company Sanaria Inc., which is focused on malaria, with the help of National Institutes of Health scientists and University of Maryland School of Medicine researchers…” (Sifferlin, 5/9).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.